These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28933367)

  • 1. Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure.
    Steggall A; Mordi IR; Lang CC
    Diseases; 2017 May; 5(2):. PubMed ID: 28933367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
    Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cardiac metabolism during myocardial ischemia.
    Chagas AC; Dourado PM; Galvão Tde F
    Curr Pharm Des; 2008; 14(25):2563-71. PubMed ID: 18991673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
    Dalal JJ; Mishra S
    Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic therapy of heart failure.
    Fragasso G; Salerno A; Spoladore R; Bassanelli G; Arioli F; Margonato A
    Curr Pharm Des; 2008; 14(25):2582-91. PubMed ID: 18991675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
    Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mitochondrial dysfunction in the treatment of heart failure.
    Sabbah HN
    Expert Rev Cardiovasc Ther; 2016 Dec; 14(12):1305-1313. PubMed ID: 27758146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure.
    Scolletta S; Biagioli B
    Biomed Pharmacother; 2010 Mar; 64(3):203-7. PubMed ID: 19954925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets.
    Fukushima A; Milner K; Gupta A; Lopaschuk GD
    Curr Pharm Des; 2015; 21(25):3654-64. PubMed ID: 26166604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of metabolic approach in patients with heart failure.
    Di Napoli P; Barsotti A
    Curr Pharm Des; 2009; 15(8):883-92. PubMed ID: 19275652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.
    Birkenfeld AL; Jordan J; Dworak M; Merkel T; Burnstock G
    Pharmacol Ther; 2019 Feb; 194():132-144. PubMed ID: 30149104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.
    Fragasso G
    Card Fail Rev; 2016 May; 2(1):8-13. PubMed ID: 28785448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.
    Lopatin YM; Rosano GM; Fragasso G; Lopaschuk GD; Seferovic PM; Gowdak LH; Vinereanu D; Hamid MA; Jourdain P; Ponikowski P
    Int J Cardiol; 2016 Jan; 203():909-15. PubMed ID: 26618252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mitochondrial dysfunction with elamipretide.
    Obi C; Smith AT; Hughes GJ; Adeboye AA
    Heart Fail Rev; 2022 Sep; 27(5):1925-1932. PubMed ID: 35037146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic therapy for heart failure].
    Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimetazidine and l‑carnitine prevent heart aging and cardiac metabolic impairment in rats via regulating cardiac metabolic substrates.
    Zhang X; Liu C; Liu C; Wang Y; Zhang W; Xing Y
    Exp Gerontol; 2019 May; 119():120-127. PubMed ID: 30639303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.